

NYRx Excluded Diagnoses

What Providers Need to Know

NYRx, the Medicaid pharmacy program, covers medically necessary FDA-approved drugs when used for Medicaid-covered indications. Certain drug, drug classes, or drug indications are excluded from coverage pursuant to federal or state law and regulation. Exclusions include:

- Agents when used for the treatment of anorexia, weight loss, or weight gain [18 NYCRR §505.3(g)(3)]

For example, but not limited to:

- GLP-1 Agonists for weight loss
 - SGLT-2 Inhibitors for weight loss
 - Adipex® or generic phentermine
 - Contrave® or generic naltrexone-bupropion
 - Qsymia® or generic phentermine-topiramate
- Agents when used for the treatment of sexual dysfunction unless such agents are used to treat a condition other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration (FDA) [NYS SSL §365-a(4)(f)]

For example, but not limited to:

- PDE-5 inhibitors (avanafil, sildenafil, tadalafil, vardenafil) for sexual dysfunction
- Agents when used for cosmetic use or hair growth [18 NYCRR §505.2(l)(5)]

For example, but not limited to:

- finasteride for alopecia
- Olumiant for alopecia areata
- Opzelura for non-segmental vitiligo

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx, the Medicaid Pharmacy Program](#)
- [Pharmacy Manual Policy Guidelines](#)

Contact Information

The NYRx Education and Outreach Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

For NYRx program-related questions and non-member-specific questions, email the NYRx Education and Outreach team at NYRxEO@magellanhealth.com.

The Education and Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach Website](#) for more information.